BCMU
TEVA icon

BlueCrest Capital Management (UK)’s Teva Pharmaceuticals TEVA Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-93,646
Closed -$4.91M – 675
2014
Q2 		$4.91M Buy
+93,646
New +$4.79M 0.17% 87

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlueCrest Capital Management (UK)'s TEVA Position: Q3 2014 in Review

BlueCrest Capital Management (UK) sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 93,646 shares — an estimated $4.91M sold.

BlueCrest Capital Management (UK) first reported a position in TEVA in Q2 2014 and held it in 1 quarter. The position peaked at $4.91M in Q2 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • BlueCrest Capital Management (UK) reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 93,646 Teva Pharmaceuticals shares in Q3 2014, an estimated $4.91M.
  • BlueCrest Capital Management (UK) first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Teva Pharmaceuticals position peaked at $4.91M in Q2 2014.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.